mk 0663 has been researched along with Disease Exacerbation in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bojkova, D; Charlesworth, B; Ciesek, S; Cinatl, J; de Bruin, N; Gribbon, P; Kannt, A; Laughey, WF; Lodhi, I; Pennick, G; Reus, P; Schiffmann, S; Schneider, AK; Sinclair, S; Talmon, S | 1 |
| Aaberge, I; Dahm, A; Dyrhol-Riise, AM; Kvale, D; Prebensen, C; Sandset, PM; Taskén, K; Trøseid, M; Ueland, T; Waalen, K | 1 |
| Gammaitoni, A; Greenwald, M; Kvien, TK; Mehta, A; Peloso, PM; Wang, H | 1 |
| Andreesen, R; Berand, A; Reichle, A; Rogenhofer, S; Vogelhuber, M; Walter, B; Wieland, WF | 1 |
| Becker, A; Dömkes, S; Hillen, U; Livingstone, E; Schadendorf, D; Zimmer, L | 1 |
| Di Silverio, F; Gentile, V; Sciarra, A | 1 |
5 trial(s) available for mk 0663 and Disease Exacerbation
| Article | Year |
|---|---|
Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial.
Topics: Adult; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Disease Progression; Etoricoxib; Female; HIV Infections; Humans; Immunity, Cellular; Male; Middle Aged; Pneumococcal Vaccines; Pyridines; Sulfones; T-Lymphocytes; Tetanus Toxoid | 2017 |
Do COX-2 inhibitors provide additional pain relief and anti-inflammatory effects in patients with rheumatoid arthritis who are on biological disease-modifying anti-rheumatic drugs and/or corticosteroids? Post-hoc analyses from a randomized clinical trial
Topics: Analgesics; Arthralgia; Arthritis, Rheumatoid; Biological Products; Colombia; Cyclooxygenase 2 Inhibitors; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Etoricoxib; Health Status; Humans; North America; Pain Measurement; Pyridines; Sulfones; Surveys and Questionnaires; Switzerland; Time Factors; Treatment Outcome | 2015 |
Modular therapy approach in metastatic castration-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Capecitabine; Deoxycytidine; Dexamethasone; Disease Progression; Drug Therapy, Combination; Etoricoxib; Fluorouracil; Humans; Kaplan-Meier Estimate; Lactones; Male; Orchiectomy; Pioglitazone; Prostatic Neoplasms; Pyridines; Sulfones; Thiazolidinediones; Treatment Outcome | 2010 |
Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Arthralgia; Disease Progression; Dose-Response Relationship, Drug; Drug Eruptions; Etoricoxib; Female; Humans; Imidazoles; Indoles; Lymphatic Metastasis; Melanoma; Middle Aged; Neoplasm Staging; Oximes; Panniculitis; Point Mutation; Proto-Oncogene Proteins B-raf; Pyridines; Skin Neoplasms; Sulfonamides; Sulfones; Vemurafenib | 2012 |
Etoricoxib and intermittent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy.
Topics: Aged; Androgen Antagonists; Anilides; Cyclooxygenase Inhibitors; Disease Progression; Etoricoxib; Humans; Male; Middle Aged; Nitriles; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Pyridines; Sulfones; Tosyl Compounds | 2008 |
1 other study(ies) available for mk 0663 and Disease Exacerbation
| Article | Year |
|---|---|
Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection.
Topics: Acetaminophen; Angiotensin-Converting Enzyme 2; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caco-2 Cells; COVID-19; Disease Progression; Enzyme Activation; Etoricoxib; Flurbiprofen; Gene Expression Regulation, Enzymologic; Humans; Ibuprofen; Male; Mice; Mice, Inbred C57BL; SARS-CoV-2; Virus Internalization | 2022 |